CONFERENCE PRESENTATIONS
Conference Presentations
Replicor personnel and collaborators attend and often present at all the major international scientific conferences where HBV or HDV is discussed. Selected presentations can be downloaded below.
| Conference | Location | Abstract/Poster | ||
|---|---|---|---|---|
| 18.11.2024 | AASLD 2024 | San Diego | Safety and efficacy of REP 2139-Mg in hepatitis D patients: reporting of extended follow-up data from the international compassionate use program | Late Breaking Oral presentation |
| 27.7.2024 | Singapore Hepatology Conference / Science of HBV Cure | Singapore | Update on NAPs: Understanding biochemical interactions and pharmacokinetics | Oral presentation |
| 27.7.2024 | Singapore Hepatology Conference / Science of HBV Cure | Singapore | The role of NAPs in therapy of Chronic HDV infection | Oral presentation |
| 7.6.2024 | European Association for the Study of the Liver 2024 Annual Meeting | Milan, Italy | Compassionate use of REP 2165-Mg in chronic HBV/HDV patients with progressive liver disease and failure to previous pegIFN therapy | Poster FRI-443 |
| 6.6.2024 | European Association for the Study of the Liver 2024 Annual Meeting | Milan, Italy | Safety and efficacy of REP 2139-Mg in hepatitis D patients with advanced liver disease: an international compassionate use program | Oral presentation OS-034 |
| 5.6.2024 | European Association for the Study of the Liver 2024 Annual Meeting | Milan, Italy | Antiviral efficacy of REP 2139-Mg and effects on HVPG in HDV/HBV coinfected patients with cirrhosis and portal hypertension non-responding to previous bulevirtide treatment | Poster WED-383 |
| 10.11.2023 | AASLD 2023 | Boston, USA | Safety and efficacy of REP 2139-Mg in association with TDF in chronic hepatitis delta patients with decompensated cirrhosis. | Poster presentation |
| 10.11.2023 | AASLD 2023 | Boston, USA | Safety and efficacy of REP 2139-Mg-based therapy in French patients with prior failure to pegIFN and or bulevirtide. | Poster presentation |
| 10.11.2023 | AASLD 2023 | Boston, USA | Safety and Efficacy of REP 2139-Mg-based therapy in Austrian patients with HBV / HDV compensated cirrhosis with prior failure to bulevirtide. | Poster presentation |
| 10.11.2023 | AAASLD 2023 | Boston, USA | REP 2139 targets the hepatitis delta virus (HDV) ribonucleoprotein (RNP) and exerts a direct antiviral effect on HDV replication. | Poster presentation |
| 10.11.2023 | AASLD 2023 | Boston, USA | Pangenomic antiviral effect of REP 2139 in CRISPR/Cas9 engineered cell lines expressing hepatitis B surface antigen. | Poster presentation |
| 30.09.2023 | Canadian Association of the Liver HBV Single Topic Conference | Calgary, Canada | Compassionate use of REP 2139-Mg in HBV / HDV / HIV co-infection: a first Canadian experience | Poster presentation |
| 23.09.2023 | International Meeting on the Molecular Biology of HBV | Kobe, Japan | REP 2139 has a direct antiviral effect on HDV replication. | Oral presentation |
| 23.09.2023 | International Meeting on the Molecular Biology of HBV | Kobe, Japan | Identification of DNAJB12 as a chaperone involved in the secretion of HBsAg and a target of the NAPs REP 2139. | Oral presentation |
| 21.06.2023 | Hepatitis Delta International Network (EASL 2023) | Vienna Austria | NAPs for treatment of chronic hepatitis D: a tale from real life? | Oral presentation |
| 24.06.2023 | EASL 2023 | Vienna, Austria | Rescue of cirrhotic HBV / HDV infection from bulevirtide failure by subcutaneous REP 2139-Mg | Poster SAT-169 |
| 24.06.2023 | EASL 2023 | Vienna, Austria | Safety and efficacy of REP 2139-Mg in association with TDF in chronic hepatitis delta patients with decompensated cirrhosis | Poster SAT-183 |
| 07.05.2023 | Digestive Disease Weekly 2023 | Chicago, USA | Rescue of cirrhotic HBV / HDV infection from bulevirtide failure by subcutaneous REP 2139-Mg | Oral presentation |
| 08.05.2023 | Digestive Disease Weekly 2023 | Chicago, USA | Rescue of cirrhotic HBV / HDV infection from bulevirtide failure by subcutaneous REP 2139-Mg | Poster of Distinction |
| 28.04.2023 | Global Hepatitis Summit 2023 | Paris France | Extended follow-up in the REP 301 and REP 401 studies demonstrates durable clinical benefit from NAP therapy | Late breaking oral presentation O105 |
| 28.04.2023 | Global Hepatitis Summit 2023 | Paris France | Rescue of cirrhotic HBV / HDV infection from bulevirtide failure by subcutaneous REP 2139-Mg | Oral presentation |
| 28.04.2023 | Global Hepatitis Summit 2023 | Paris France | Safety and efficacy of REP 2139-Mg in association with TDF in patients with chronic hepatitis delta and decompensated cirrhosis | Oral presentation |
| 15.02.2023 | APASL 2023 | Taipei, Taiwan | Safety and efficacy of REP 2139-Mg in association with TDF in patients with chronic hepatitis delta and decompensated cirrhosis | Poster OC-29 (Award of excellence) |
| 18.02.2023 | APASL 2023 | Taipei, Taiwan | Rescue of cirrhotic HBV / HDV infection from bulevirtide failure by subcutaneous REP 2139-Mg | Oral presentation OC-28 (Awarded best oral presentation) |
| 1.12.2022 | World Antiviral Conference | San Diego, USA | HBsAg Loss and Transaminase Flares: Therapeutic Implications for Functional Cure of HBV | Oral Presentation |
| 04.11.2022 | AASLD 2022 | Washington DC, USA | Compassionate use of subcutaneously administered REP 2139-Mg in cirrhotic HBV / HDV co-infection | Poster Presentation |
| 04.11.2022 | AASLD 2022 | Washington DC, USA | Identification of the Hsp40 chaperone DNAJB12 in the functional mechanism of the nucleic acid polymer REP 2139 | Poster Presentation |
| 04.11.2022 | AASLD 2022 | Washington DC, USA | Defining the mechanism of action of the Hsp40 chaperones DNAJB12 and DNAJB14 in the assembly and secretion of Hepatitis B subviral particles | Poster Presentation |
| 07.10.2022 | DeltaCure 2022 | Milan, Italy | Rescue of cirrhotic HBV / HDV infection from bulevirtide failure by subcutaneous REP 2139-Mg | Poster Presentation |
| 07.10.2022 | DeltaCure 2022 | Milan, Italy | A biochemical basis for the hepatoprotective effects of REP 2139 during host mediated transaminase flares | Poster Presentation |
| 07.10.2022 | DeltaCure 2022 | Milan, Italy | Sustained off therapy control of HBV and HDV infection following removal of NAP-based therapy in cirrhotic HBV / HDV co-infection | Poster Presentation |
| 20.09.2022 | 2022 International HBV meeting | Paris, France | Identification of the Hsp40 chaperone DNAJB12 in the functional mechanism of the antiviral nucleic acid polymer REP 2139 and establishment of its mechanism of action in the secretion of HBsAg. | Poster Presentation |
| 19.09.2022 | 2022 International HBV meeting | Paris, France | Understanding mechanisms and effects of oligonucleotide-based drugs in chronic HBV infection | Poster Presentation |
| 19.09.2022 | 2022 International HBV meeting | Paris, France | Sustained off therapy control of HBV and HDV infection following removal of NAP-based therapy in cirrhotic HBV / HDV co-infection | Poster Presentation |
| 19.09.2022 | 2022 International HBV meeting | Paris, France | Compassionate use of subcutaneously administered REP 2139-Mg in cirrhotic HBV / HDV co-infection | Poster Presentation |
| 22.06.2022 | 21st meeting of the Hepatitis Delta International Network | London, UK | Compassionate use of subcutaneous REP 2139-Mg in cirrhotic HBV / HDV coinfection | Oral Presentation |
| 31.05.2022 | 2022 Science of HBV Cure | Singapore | Achieving clearance of subviral particles with NAPs: A critical milestone for HBsAg loss and functional cure | Oral Presentation |
| 25.04.2022 | 2nd Annual Chronic HBV Drug Development Congress | Boston, USA | Workshop A: Agents in development targeting HBsAg | Oral Presentation |
| 25.04.2022 | 2nd Annual Chronic HBV Drug Development Congress | Boston, USA | Workshop B: Clinical progress in targeting cccDNA | Oral Presentation |
| 27.04.2022 | 2nd Annual Chronic HBV Drug Development Congress | Boston, USA | HBsAg loss and transaminase flares: Critical milestones for functional cure. | Oral Presentation |
| 20.04.2022 | World Vaccine Congress | Washington DC, USA | HBsAg Loss and Transaminase Flares: Therapeutic Implications for Functional Cure of HBV | Oral Presentation |
| 7.12.2021 | HepDart 2021 | Cabo San Lucas, Mexico | Oligonucleotide-based strategies for targeting HBsAg: Understanding mechanisms and effects | Oral Presentation |
| 7.12.2021 | HepDart 2021 | Cabo San Lucas, Mexico | Ph dependent target interaction of NAPs | Poster 1 |
| 7.12.2021 | HepDart 2021 | Cabo San Lucas, Mexico | Compassionate use of subcutaneously administered REP 2139-Mg in HBV / HDV infection | Poster 7 |
| 2.12.2021 | World Antiviral Conference | San Diego | HBsAg Loss and Transaminase Flares: Therapeutic Implications for Functional Cure of HBV | Oral Presentation |
| 15.11.2021 | AASLD 2021 (TLMdX) | Online | Transition of REP 2139-Mg to subcutaneous administration | Late Breaking Poster LP-14 |
| 15.11.2021 | AASLD 2021 (TLMdX) | Online | HBsAg response during NAP therapy predicts functional cure | Presidential poster of distinction 840 |
| 15.11.2021 | AASLD 2021 (TLMdX) | Online | Antiviral responses during TDF monotherapy in the REP 401 study | Poster 805 |
| 15.11.2021 | AASLD 2021 (TLMdX) | Online | Ph dependent target interaction of NAPs | Poster 836 |
| 13.10.2021 | Science of HBV Cure (Singapore Hepatitis Conference) | Online | Nucleic acid polymers: Biochemistry, molecular mechanism and application in the achievement of functional cure | Oral presentation |
| 28.09.2021 | International HBV Meeting 2021 | Online | Ph-dependent interaction of NAPs with the HSP40 chaperone DNAJB12 | Poster presentation |
| 18.06.2021 | Global Hepatitis Summit / ISVHLD 2021 | Online | Experimental endpoint analysis during NAP-based therapy | Oral presentation |
| 23.06.2021 | EASL ILC 2021 | Online | HBV kinetics during NAP-based therapy | Poster 1837 |
| 5.05.2021 | Chronic Hepatitis B drug development (Hanson Wade) | Online | HBsAg, Subviral Particles and Their Clearance in Establishing Functional Cure of Chronic HBV Infection | Oral presentation |
| 13.11.2020 | TLMdX (AASLD 2020) | Online | NAP target identification | Late breaking poster LP42 |
| 13.11.2020 | TLMdX (AASLD 2020) | Online | Compassionate use of NAPs in cirrhotic HBV / HDV coinfection | Poster 0827 |
| 13.11.2020 | TLMdX (AASLD 2020) | Online | HBsAg isoform analysis in REP 301 and REP 401 studies | Poster 0819 |
| 13.11.2020 | TLMdX (AASLD 2020) | Online | In vitro evaluation of NAPs in the absence of virion assembly | Poster 0818 |
| 27.08.2020 | Digital ILC EASL 2020 | Online | Experimental virologic endpoints in the REP 301/301-LTF and REP 401 studies | Late breaking poster |
| 16.7.2020 | Blumberg Institute HBV Seminar Series | Webinar | Understanding HBsAg and Subviral Particles: Key players in chronic HBV infection, Key targets in achieving functional cure of HBV | Slide deck |
| 16.7.2020 | Blumberg Institute HBV Seminar Series | Webinar | Understanding HBsAg and Subviral Particles: Key players in chronic HBV infection, Key targets in achieving functional cure of HBV | Seminar video |
| 10.12.2019 | HEPDART 2019 | Kauai, USA | Beneficial effects of transaminase flares and predicting virologic control and functional cure during NAP therapy | Replicor REP 401 301 Flares versus outcome poster O3 HEPDART 2019 FINAL |
| 10.12.2019 | HEPDART 2019 | Kauai, USA | Final follow-up data from REP 401 (HBV) and REP 301-LTF (HBV / HDV) | Replicor REP 401 301-LTF Complete follow-up poster P15 HEPDART 2019 FINAL |
| 9.12.2019 | HEPDART 2019 | Kauai, USA | Beneficial effects of transaminase flares and predicting virologic control and functional cure during NAP therapy (ORAL) | Replicor flares vs outcomes O3 Hepdart 2019 FINAL |
| 09.12.2019 | HEPDART 2019 | Kauai, USA | Detailed data presentation of transfection artifacts with NAPs in vitro | Assessing the in vitro activity of NAPs in HBV |
| 09.12.2019 | HEPDART 2019 | Kauai, USA | Accurately assessing in vitro activity of NAPs Poster | Accurately assessing in vitro activity of NAPs Poster |
| 09.11.2019 | HDIN meeting at AASLD 2019 | Boston, Canada | REP 301-LTF 3.5 year follow-up | REP 301-LTF HDIN AASLD 2019 FINAL |
| 08.11.2019 | AASLD 2019 | Boston, USA | REP 301-LTF 3.5 year follow-up | REP 301-LTF 3.5 year follow-up AASLD 2019 FINAL |
| 06.11.2019 | 2019 HBV Cure Workshop | Toronto, Canada | Clinical and mechanistic update on NAPs | Replicor REP 301-LTF REP 401 flares update HBV Cure 2019 FINAL |
| 04.10.2019 | 2019 International HBV meeting | Melbourne, Australia | REP 401 study final results and predicting functional cure of HBV. | REP 401 final results HBV meeting 2019 Oral |
| 03.10.2019 | 2019 International HBV meeting | Melbourne, Australia | Transaminase flares in the absence of HBsAg during REP 2139 + pegIFN therapy predict functional cure of HBV. | Replicor HBV meeting 2019 flares vs outcome Poster 242 |
| 03.10.2019 | 2019 International HBV meeting | Melbourne, Australia | In vitro effects of REP 2139 on the HBV lifecycle. | INRS Replicor HBV meeting 2019 in vitro Poster 241 |
| 08.06.2019 | Science of HBV Cure | Singapore | REP 401 study final results and predicting functional cure of HBV | REP 401 final results SHC 2019 |
| 12.04.2019 | EASL ILC 2019 | Vienna, Austria | Safety and Tolerability of Transaminase flares during therapy of HBV | REP 301 401 Transaminases EASL 2019 Poster FRI-211 |
| 12.04.2019 | EASL ILC 2019 | Vienna, Austria | REP 401 trial + MOA update (Poster) | REP 401 EASL 2019 Poster FRI-210 |
| 10.04.2019 | HDIN Meeting at EASL ILC 2019 | Vienna, Austria | Safety and efficacy of transaminase flares in HBV and HDV. | REP 301 401 transaminase flares HDIN EASL 2019 |
| 08.03.2019 | EASL / AASLD HBV Endpoints 2019 | London, UK | REP 401 trial + MOA update (Oral) | REP 401 EASL AASLD Endpoints 2019 Oral OP-02 FINAL |
| 08.03.2019 | EASL / AASLD HBV Endpoints 2019 | London, UK | REP 401 trial + MOA update (Poster) | REP 401 EASL AASLD Endpoints 2019 Poster OP-02 FINAL |
| 08.03.2019 | EASL / AASLD HBV Endpoints 2019 | London, UK | Safety and Tolerability of Transaminase flares during therapy of HBV | REP 301 401 Transaminases EASL AASLD Endpoints 2019 Poster P03-01 FINAL |
| 23.02.2019 | APASL 2019 | Manila, Philippines | Achieving functional cure with REP 2139 | REP 401 APASL 2019 FINAL |
| 10.11.2018 | Hepatitis Delta International Network Meeting (AASLD 2018) | San Francisco, USA |
REP 301-LTF update REP 2139-Mg transition to SC | HDIN AASLD 2018 |
| 9.11.2018 | AASLD 2018 | San Francisco, USA | Achieving functional cure with REP 2139 | REP 401 AASLD 2018 |
| 7.11.2018 | HBV Cure Workshop 2018 | Toronto, Canada | REP 401 study interim follow-up update | HBV Cure Workshop 2018 |
| 6.10.2018 | 2018 HBV International Meeting | Taormina, Italy | Achieving functional cure with REP 2139 | REP 2139 clinical HBV INT 2018 |
| 5.10.2018 | 2018 HBV International Meeting | Taormina, Italy | REP 2139 mechanism of action in vitro | REP 2139 vs HBsAg HBV INT 2018 |
| 4.10.2018 | 2018 HBV International Meeting | Taormina, Italy | Apolipoproteins in HBsAg secretion in vitro | Apos vs HBsAg HBV INT 2018 |
| 25.09.2018 | Discovery on Target 2018: Targeting HBV | Boston, USA | Achieving functional cure with REP 2139 | CHT Targeting HBV 2018 |
| 15.06.2018 |
Global Hepatitis Summit 2018 (16th International Symposium of Viral Hepatitis and Liver Disease) | Toronto, Canada | Updated follow-up analysis in the REP 401 protocol. | GHS 2018 presentation |
| 09.06.2018 |
Science of HBV Cure (Singapore Hepatitis Conference) | Singapore, Singapore | Achieving functional control of HBV and HDV infection with REP 2139-based combination therapy | Combination therapy presentation |
| 08.06.2018 |
Science of HBV Cure (Singapore Hepatitis Conference) | Singapore, Singapore | REP 2139 mechanistic insights and effects in monotherapy | Monotherapy presentation |
| 13.04.2018 | EASL ILC 2018 | Paris, France | Modelling viral kinetics during REP 2139-Ca monotherapy | Poster FRI-324 |
| 13.04.2018 | EASL ILC 2018 | Paris, France | Updated follow-up data in the REP 301-LTF study (HBV/HDV). | Poster FRI-326 |
| 13.04.2018 | EASL ILC 2018 | Paris, France | Updated follow-ip data in the REP 401 study (HBV) | Poster FRI-343 |
| 07.12.2017 | HEPDART 2017 | Kona, HI, U.S.A. | REP 401 Interim follow-up update | Presentation O-19 |
| 21.10.2017 | AASLD 2017 | Washington, DC, U.S.A | REP 401 Interim follow-up update | Poster LB-24 |
| 21.10.2017 | AASLD 2017 | Washington, DC, U.S.A | Update on NAP mechanism of action in HBV | Poster 957 |
| 21.10.2017 | AASLD 2017 | Washington, DC, U.S.A | Update on NAP mechanism of action in HDV | Poster 942 |
| 25.09.2017 | CHT Discovery on Target:Targeting HBV | Boston, U.S.A. | Targeting HBsAg secretion with NAPs: Drug development update | Presentation |
| 05.09.2017 | HBV International Meeting 2017 | Washington DC, U.S.A. | Modelling post-entry effects of NAPs against HBV infection in vitro. | Poster P-146 |
| 05.09.2017 | HBV International Meeting 2017 | Washington DC, U.S.A. | Activity of NAPs against HDV in vivo | Poster P-144 |
| 05.09.2017 | HBV International Meeting 2017 | Washington DC, U.S.A. | NAPs interact with small and large hepatitis delta antigen | Poster P-145 |
| 05.09.2017 | HBV International Meeting 2017 | Washington DC, U.S.A. | HBsAg Quasispecies evolution in the REP 102 trial. | Poster P-127 |
| 05.09.2017 | HBV International Meeting 2017 | Washington DC, U.S.A. | Mathematical modelling of viral dynamics in the REP 102 protocol. | Poster P-148 |
| 05.09.2017 | HBV International Meeting 2017 | Washington DC, U.S.A. | Clinical NAP Summary (critical role for HBsAg suppression in achieving functional cure. | Poster P-147 |
| 07.09.2017 | HBV International Meeting 2017 Satellite Symposium | Washington DC, U.S.A. | Clinical NAP Summary (critical role for HBsAg suppression in achieving functional cure. | Presentation O-198. |
| 20.04.2017 | HDIN meeting (EASL 2017) | Amsterdam, The Netherlands | REP 301 / 301-LTF update HDIN (EASL 2017) | Presentation HDIN (EASL 2017) |
| 20.04.2017 | EASL 2017 | Amsterdam, The Netherlands | REP 301 / 301-LTF update LBP-507 | Poster LBP-507 |
| 20.04.2017 | EASL 2017 | Amsterdam, The Netherlands | REP 401 update EASL 2017 THU-154 | Poster THU-154 |
| 20.04.2017 | EASL 2017 | Amsterdam, The Netherlands | REP 102 HBsAg deep sequencing EASL 2017 THU-155 | Poster THU-155 |
| 20.04.2017 | EASL 2017 | Amsterdam, The Netherlands | NAP post-entry activity modelling in vitro EASL 2017 THU-156 | Poster THU-156 |
| 20.04.2017 | EASL 2017 | Amsterdam, The Netherlands | Modeling HBsAg and HDV DNA kinetics EASL 2017 THU-173 | Poster THU-173 |
| 18.02.2017 | APASL 2017 | Shanghai, China | Update on Safety and Efficacy in the REP 401 protocol | APASL 2017 oral presentation |
| 15.11.2016 | AASLD 2016 | Boston, U.S.A. | Preliminary efficacy and safety from the REP 401 trial: REP 2139 / REP 2165 + peg-IFN + TDF in HBeAg negative HBV infection | AASLD 2016 oral presentation |
| 14.11.2016 | AASLD 2016 | Boston, U.S.A. | Follow-up results from the REP 301 trial: REP 2139 + peg-IFN in HBV / HDV co-infection | AASLD 2016 REP 301 poster |
| 22.9.2016 | HBV 2016 | Seoul, Korea | Effects of nucleic acid polymers on hepatitis B virus entry in HepaRG cells and primary human hepatocytes | HBV 2016 HBV Poster |
| 22.9.2016 | HBV 2016 | Seoul, Korea | Inhibition of Hepatitis Delta Virus infection by Nucleic Acid Polymers – an in vitro analysis – | HDV 2016 HDV Poster |
| 4.15.2016 | EASL 2016 | Barcelona, Spain | Update on the safety and efficacy of REP 2139 monotherapy and subsequent combination therapy with pegylated interferon alpha-2a in Caucasian patients with chronic HBV / HDV co-infection | Poster FRI-105 EASL 2016 |
| 4.14.2016 | EASL 2016 | Barcelona, Spain | Nucleic acid-based polymers effective against hepatitis B virus infection in patients do not harbour immune stimulatory properties in primary isolated blood or liver cells | Poster THU-204 EASL 2016 |
| 4.14.2016 | EASL 2016 | Barcelona, Spain | Achievement of surface antigen clearance in the liver by combination therapy with REP 2139-Ca and nucleoside analogues against chronic hepatitis B | Poster THU-177 EASL 2016 |
| 2.22.2016 | APASL 2016 | Tokyo, Japan | On-treatment reduction of HBsAg and HDV RNA with REP 2139-Ca and pegylated interferon alpha 2a in Caucasian Patients with chronic HBV / HDV co-infection | Replicor REP 301 APASL 2016 O-130web |
| 2.22.2016 | APASL 2016 | Tokyo, Japan | Potentiation of antiviral effect in vivo against HBV by combined therapy with REP 2139-Ca and nucleos(t)ide analogues | Replicor APASL 2016 Combo NAPS In vivo P-0329 |
| 8.12.2015 | HEP DART 2015 | Wailea, Hawaii | On-Treatment Reduction of HBsAg and HDV RNA with REP 2139-Ca and Pegylated Interferon alpha 2a in Caucasian Patients with Chronic HBV/HDV | REP301 HEPDART 2015 FINAL (Abstract 60) |
| 8.12.2015 | HEP DART 2015 | Wailea, Hawaii |
Combination Therapy with the Nucleic Acid Polymer REP 2139-Ca and Nucleos(t)ide Analogues Improves Antiviral Responses Against Hepatitis B In Vivo | COMBO NAPS HEPDART 2015 FINAL (Abstract 114) |
| 11.15.2015 | AASLD 2015 | San Francisco | Update on the safety and efficacy of REP 2139 monotherapy and subsequent combination therapy with pegylated interferon alpha-2a in chronic HBV / HDV co-infection in Caucasian patients. | Replicor REP 301 AASLD 2015 (Abstract 31) |
| 10.7.2015 | Int. Mol. Biol. HBV 2015 | Bad Nauheim | Antiviral effects of nucleic acid polymers on Hepatitis B virus infection in vitro (P-217) | Replicor NAPs in vitro (HBV) HBV 2015 (P-217) |
| 10.7.2015 | Int. Mol. Biol. HBV 2015 | Bad Nauheim | Immunostimulatory properties of nucleic acid polymers (P-221) | Replicor NAPs Immunostimulation HBV 2015 (P-221) |
| 10.7.2015 | Int. Mol. Biol. HBV 2015 | Bad Nauheim | Benefit of interferon-free, nucleic acid polymer-based combination therapy for chronic Hepatitis B (P-238) | Replicor NAPs + NUCs in vivo HBV 2015 (P-238) |
| 10.7.2015 | Int. Mol. Biol. HBV 2015 | Bad Nauheim | Modifications of nucleic acid polymers decrease liver accumulation without affecting antiviral activity (P-239) | Replicor Diff NAPs in vivo HBV 2015 (P-239) |
| 10.7.2015 | Int. Mol. Biol. HBV 2015 | Bad Nauheim | Activity of various nucleic acid polymers in blocking hepatitis delta virus entry in vitro (P-242) | Replicor NAPs in vitro (HDV) HBV 2015 (P-242) |
| 6.25.2015 | ISVHLD 2015 | Berlin |
REP 2139 monotherapy and combination therapy with pegylated interferon: Safety and potent reduction of HBsAg and HDV RNA in Caucasian Patients with chronic HBV / HDV co-infection (O-09) | ISVHLD 2015 Presentation |
| 4.25.2015 | EASL ILC 2015 | Vienna | Significant reduction of HBsAg and HDV RNA by REP 2139-Ca in Caucasian patients with HBV / HDV co-infection (LO2) | EASL 2015 Presentation |
| 4.25.2015 | EASL ILC 2015 | Vienna | HBV RNA analysis in Asian patients treated with REP 2139-Ca (O114) | EASL 2015 Presentation |
| 4.25.2015 | EASL ILC 2015 | Vienna | Serum cytokine response in Asian HBV infected patients treated with REP 2139-Ca (P0659) | EASL 2015 Poster |
| 4.25.2015 | EASL ILC 2015 | Vienna | Pre-clinical assessment of various NAPs in HBV infection (P0542) | EASL 2015 Poster |
| 4.25.2015 | EASL ILC 2015 | Vienna | Activity of NAPs against HDV infection in vitro (LP26) | EASL 2015 Poster |
| 4.23.2015 | EASL ILC 2015 | Vienna | Activity of NAPs against HBV infection in vitro (P0556) | EASL 2015 Poster |
| 4.10.2015 | Lancet Hepatitis Summit 2015 | Shanghai | REP 2055 / REP 2139-Ca Asian Clinical data update | Lancet Poster |
| 10.12.2014 | OTS 2014 | San Diego | REP 2055 / REP 2139-Ca Asian Clinical data update | OTS Presentation |
| 5.12.2013 | TIDES 2013 | Boston | REP 2055 / REP 2139-Ca Efficacy and Safety | TIDES Presentation |
| 4.26.2013 | EASL 2013 | Amsterdam | REP 2139-Ca Asian Clinical data | EASL Poster |